Coronavirus Disease 2019: An Overview of the Complications and Management

Huimin Shao¹, Hany Sadek Ayoub Ghaly¹†, Pegah Varamini¹,²*

¹School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
²Sydney Nano Institute, The University of Sydney, Sydney, NSW 2006, Australia
†These authors contributed equally to this work.

*Corresponding Author: Dr. Pegah Varamini, Email: pegah.varamini@sydney.edu.au, Tel: +61 2 8627 0809, Fax: +61 2 9351 4391

Received: February 3, 2021; Accepted: April 6, 2021; Published: May 3, 2021 DOI: 10.36922/itps.v4i1.1037

Copyright: © 2021 Shao, et al. This is an open-access article distributed under the terms of the Attribution NonCommercial 4.0 International 4.0 (CC BY-NC 4.0), which permits all non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract:
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Since the first report of COVID-19 emerging in Wuhan, China, authorities in 216 countries and territories have reported about 47.3 million COVID-19 cases and 1.2 million deaths. The WHO guidelines for the management of COVID-19 are very limited to recommendations for managing symptoms and advice on careful management of pediatric patients, pregnant women, and patients with underlying comorbidities. There is no approved treatment for COVID-19 and guidelines vary between countries. In this review, first, a brief overview is provided on the basic knowledge about the virus, clinical features of the disease, and different diagnostic methods. Then, the relationship between COVID-19, various body systems, and other complications is discussed. Finally, different management strategies are discussed, including those drawn on computational chemistry analyses, pre-clinical investigations, and clinical trials which involve pharmacological and non-pharmacological interventions. In conclusion, despite the recent approval of different vaccine candidates, more virological characteristics of SARS-CoV-2 are required to be explored, which may result in the discovery of more potential therapeutic targets leading to safer and more effective treatment to COVID-19.

Keywords: Coronavirus disease 2019, Viral infection, Coronavirus, Severe acute respiratory syndrome coronavirus-2, Vaccine, Antiviral agents

1. Introduction

The first agent from the beta-coronaviruses’ family to infect human beings was severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). This virus caused an outbreak of the disease called SARS in China in 2003. Another virus from the same family appeared in 2012, called Middle East respiratory syndrome-related coronavirus (MERS-CoV), and it causes the MERS disease [1]. As of April 2020, MERS has taken the lives of 858 persons. On the same date, SARS-CoV-1 killed 774 people, according to the World Health Organization (WHO). A new member of the coronaviruses’ family emerged in December 2019 in Wuhan, China. This member caused unknown pneumonia cases until January 2020, when the virus was isolated and identified, and it was called SARS-CoV-2. SARS-CoV-2 causes an acute respiratory illness called coronavirus disease 2019 (COVID-19) [2]. SARS-CoV-2 is highly contagious in comparison to SARS-CoV-1 and MERS-CoV. In March 2020,
the COVID-19 was considered a pandemic by the WHO. SARS-CoV-2, from December 2019 to July 2020, infected 13,049,106 and killed 571,807 as per the WHO. It is evident that COVID-19 is a severe global health issue that should be dealt with wisely and quickly. In this review, we aim to give the readers an overview of COVID-19 in addition to its clinical features, diagnosis, complications, and relationship to comorbidities. A section of this article discusses different strategies toward the management of the disease, including results from computational chemistry analysis, pre-clinical investigations, and clinical trials.

SARS-CoV-2 belongs to the same family as SARS-CoV-1 and MERS-CoV, which is beta-coronavirus lineage $\beta$. SARS-CoV-2 is an enveloped virus with a single positively-charged RNA genome. Its particle is round or oval and has a diameter range of 60-140 nm [3]. It has the following genome structure: 5'UTR-ORF1a-ORF1b-S gene-E gene-M gene-N gene-3'UTR. S gene codes for the spike (S) protein, which is an essential surface protein on the viral cell responsible for interacting with host cell surface receptors (mainly angiotensin-converting enzyme 2 or [ACE2]) for viral entry into host cells. The M protein is essential for nutrients transport across the cell membrane, E protein for viral release from the host cells, and N protein for maintaining genome stability [4].

COVID-19 is the severe acute respiratory syndrome caused by SARS-CoV-2 infections. Symptoms of COVID-19 include fever, dry cough, fatigue, nausea, and diarrhea. SARS-CoV-2 spreads from the bronchi to the alveoli and then to other body organs causing acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury (AKI), secondary bacterial infection, and shock, and it may lead to death in some cases [5,6]. In addition to direct organ failure caused by SARS-CoV-2, it also induces a robust inflammatory response in the lungs, which results in lung injury. This inflammatory response is accompanied by very high levels of cytokines, including interleukin (IL)-1$\beta$, IL-6, IL-12, and interferon (IFN)-$\gamma$ [7].

SARS-CoV-2 is transferred among human beings mainly by droplets. However, its RNA was found in the feces of some patients indicating that live viruses may be present in the feces, which means that another route for viral transfer between people may be present [8]. Several studies indicated that men are more affected by COVID-19 than women [2,6]. More severe illness is present in those with comorbidities such as diabetes, cardiovascular diseases, hypertension, and malignancy. Blood tests show significant changes in the levels of circulating molecules. Different studies showed different fatality rates for COVID-19, but generally speaking, it is between 2.5 and 5.5% [2,6,9]. The mortality rate is affected by age, comorbidities, and probably genetic differences [6].

This review briefly discusses some clinical features of COVID-19, current diagnostic methods and different complications caused by the disease. Moreover, we described computational studies that refer to some existing compounds as potential agents against SARS-CoV-2, such as didanosine, remdesivir, IDX-184, itacitinib, and adeflavin. The pre-clinical trials’ section provides an insight into the efficacy of some existing compounds under investigation against SARS-CoV-2, in addition to their efficacy against MERS-CoV and SARS-CoV-1 as an indication of their potential efficacy against SARS-CoV-2. We highlighted the roles of chloroquine (CQ), hydroxychloroquine (HCQ), and remdesivir as potential agents against COVID-19. Finally, the clinical trials’ section summarizes results from clinical trials testing different agents against COVID-19. In this review, we mainly focused on those agents used to treat, in addition to agents used to manage COVID-19.

2. Clinical features

Zhut et al. analyzed 38 large studies, including 3062 patients, to identify the clinical features of COVID-19 [2]. The results are summarized in Tables 1. Studies show that more men get affected by COVID-19 than women, as 56.9% of COVID-19 patients are men while 43.1% of the patients are women.

2.1. Presentations

The presentation of COVID-19 varies among different people at illness onset, but most patients
experience some common signs and symptoms during the course of the disease. These include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Table 1 shows signs and symptoms observed in most COVID-19 patients, with the percentages of patients experiencing each symptom. It demonstrates that fever, cough, and fatigue were among the most common symptoms, while nausea, vomiting, and diarrhea were the most common symptoms affecting the digestive system.

2.2. Blood test abnormalities

Table 1 depicts the most common abnormalities in the blood test results in COVID-19 patients. It is essential to highlight that inflammatory indicators are high in most patients. Besides, liver and kidney function tests are abnormal in some patients. This table also shows that most of the COVID-19 patients get bilateral lung lesions and lastly, the patients have a mortality rate of 5.5%.

3. Diagnosis

3.1. Reverse transcription-polymerase chain reaction (RT-PCR)

According to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8) issued by the National Health Commission and State Administration of Traditional Chinese Medicine on August 19, 2020, real-time fluorescence RT-PCR detection of new coronavirus nucleic acid or the fact that the viral gene sequence is highly homologous to the known novel coronaviruses can be regarded as the standard of the clinical diagnosis of COVID-19. The new coronavirus RNA can be detected in nasopharyngeal swabs, sputum, lower respiratory tract secretions, blood, and feces. RT-PCR might show a false-negative detection rate at about 30-50% because of sampling position and possible low load of virus (e.g., the virus is not at the replication phase at the time of detection). Hence, it is recommended to obtain specimens from the lower respiratory tract, such as sputum and air tract extraction, to increase the accuracy of RT-PCR tests [10]. However, RT-PCR is time consuming and has a complex confirmation process. Sometimes it needs a second test after 24 h if the first sample taking from both throat and lower respiratory tract is negative [11].
3.2. Computed tomography (CT)

CT is another vital tool in the diagnosis of COVID-19. It is easy to perform, and a scan takes only 5 s. Furthermore, it decreases the possibility of medical staff exposure to the virus. Several indicators, such as small subpleural ground-glass opacities (GGO), are essential in the diagnosis of asymptomatic patients [12].

3.3. Serological chemiluminescence immunoassay (CLIA)

As both Immunoglobulin M (IgM) and IgG play important roles in long-term immunity and immunological memory, serological detection of IgM and IgG can be another potential way to diagnose COVID-19 [13]. According to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8) issued by the National Health Commission and State Administration of Traditional Chinese Medicine on August 19, 2020, if the novel coronavirus-specific IgM and IgG are detected in serum, and, compared to the acute phase, the titration of the novel coronavirus specific IgG reaches at least 4-fold increase during convalescence, suspected cases can be diagnosed as COVID-19 [10].

4. Complications of COVID-19

Yang et al. investigated the cause of death in 92 patients who died from COVID-19 [1]. Results showed that 79.3% of deceased patients died because of ARDS. About 7.6% died of septic shock. Myocardial infarction was the cause of death in 6.5% of patients, followed by heart failure (2.2%), multiple organ dysfunction syndrome (MODS) (2.2%), and pneumothorax (1.1%). Inflammatory markers such as procalcitonin, C-reactive protein, and serum amyloid A were significantly high in 39 patients. Thirty-one patients had abnormally high myocardial enzymes during hospitalization. Only 15 cases had an abnormal liver function or total bilirubin. The acute renal injury occurred in 14 patients. Furthermore, 14 patients experienced MODS. It is suggested by the authors that the hyper-inflammatory condition (including cytokine storm) caused by SARS-CoV-2 may be responsible for these complications in addition to direct viral damage to host cells, especially cells with high ACE2 expression such as lung cells, bile duct cells, and renal tubules.

4.1. Impact of COVID-19 on renin angiotensin (Ag) aldosterone system (RAAS)

The RAAS starts with renin cleaving angiotensinogen to Ag 1 which is further cleaved by ACE to Ag 2. Ag II binds to Ag II receptors 1 and 2 [14].

ACE2 is mainly present in the lungs and small intestines and it converts Ag II to Ag (1 – 7), which binds to Mas receptor producing anti-inflammatory and anti-fibrinolytic activities. On the other hand, activation of Ag II receptors by Ag II results in pro-inflammatory and pro-fibrinolytic activities [14]. As discussed earlier, ACE2 is the main host receptor responsible for the internalization of SARS-CoV-2 through interaction with the S protein on the viral cell surface [4].

The binding of SARS-CoV-2 to ACE2 causes exhaustion of ACE2. A study showed that the loss of ACE2 expression causes severe lung injury [15]. Moreover, injecting mice with recombinant human ACE2 protein resulted in a decrease in acute lung injury expressed by increased lung elasticity and reduced pulmonary edema formation. On the other side, Ag II level was extremely high in the serum of COVID-19 patients due to the S protein, as confirmed by two studies [16,17]. High Ag II levels resulted in severe acute lung injury and pulmonary edema while blocking of Ag II receptor 1 by a specific inhibitor decreased lung injury and edema in mice [16,17].

Ag-converting enzyme inhibitors (ACEI) and Ag II receptor blockers (ARBs) represent two classes of medications widely used in the management of cardiovascular diseases. AECIs act by reducing the production of Ag II through inhibition of ACE while ARBs directly block Ag II receptors [14]. It is proposed now that ACEI/ARBs can reduce lung injury caused by SARS-CoV-2 through their mechanisms of action that attenuate Ag II action [14].

Another point of view proposed by some researchers include that blocking of ACE by ACEI or blocking of Ag II receptor by ARBs can lead to overexpression of ACE2, which may increase the invasion of SARS-CoV-2 to host cells [18,19]. Furthermore,
N-(2-Aminoethyl)-1-aziridineethanamine, which is an experimental ACE2 inhibitor, was investigated for its use in treating cardiovascular disease and its activity against SARS. This agent is now being investigated to help reduce host cell invasion by SARS-CoV-2 [20]. Clinical trials are needed to investigate whether ACEI/ARBs are beneficial in reducing the mortality rate in COVID-19 patients or not.

4.2. Impact of COVID-19 on the cardiovascular system

According to the WHO, cardiovascular patients have worse outcomes from SARS-CoV-2 infections with an increase in mortality rate by 5 – 10 folds. COVID-19 causes death in 10.5% of patients with cardiovascular complications and 6% of hypertensive patients [21].

Cardiovascular patients are more liable to get viral illness and are at high risk of developing cardiovascular events during or after a viral infection. For example, acute myocardial infarction is common in cardiovascular patients following influenza infection [22]. In one study in China, 32.7% of hypertensive patients got severe COVID-19 in comparison to 12.6% of non-hypertensive patients [9]. Around 33.9% of COVID-19 patients with cardiovascular diseases had a severe illness in comparison to 15.3% of COVID-19 patients without cardiovascular disease. In the same study, 22% of COVID-19 patients with cardiovascular diseases reached the endpoint (death or admission to intensive care unit [ICU] or need for invasive ventilation) compared to only 7.7% of COVID-19 non-cardiovascular patients. In hypertensive patients with COVID-19, 19.7% reached the endpoint compared to 5.9% in non-hypertensive patients [9]. On the other hand, SARS-CoV-2 infection can lead to cardiovascular complications, as discussed earlier.

While SARS-CoV-1 can replicate in the hearts of 35% of patients, it is still unknown whether SARS-CoV-2 can do the same [23]. This leads to the possibility that the main reason for cardiovascular complications in COVID-19 patients is the hyper-inflammatory condition caused by SARS-CoV-2 in addition to the loss of circulating ACE2 in myocardial tissue (as an immune response to decrease viral replication), which increases the probability for heart failure. Furthermore, the high level of Ag II leads to hypertension and thrombosis. The release of troponin to the blood is the main sign of myocardial injury caused by SARS-CoV-2 [24].

4.3. COVID-19 and metabolic diseases

It is well known that diabetic patients are more prone to viral and bacterial respiratory tract infections [25]. In diabetic patients infected with SARS-CoV-1, hyperglycemia was associated with a high mortality rate which may increase by up to 3-folds in response to hyperglycemia [26,27]. A study on MERS Saudi patients showed that diabetes was strongly associated with a high rate of mortality [28].

Regarding SARS-CoV-2, type 2 diabetic patients suffered from more severe illness of COVID-19 in comparison to non-diabetic patients. This was assessed by blood counts, coagulation parameters and inflammation biomarkers [29]. In the USA, about 32% of COVID-19 patients in the ICU had diabetes mellitus, 24% of COVID-19 patients in the hospital but not in the ICU had diabetes, and only 6% of non-hospitalized patients had diabetes which clearly shows that diabetes was associated with poorer prognosis of SARS-CoV-2 infection [30].

On the other hand, viral respiratory tract infections and the medications used, such as glucocorticoids, lead to impaired insulin sensitivity which requires adjusting the doses of glucose-lowering agents. In addition, viral respiratory tract infections lead to an increase in mortality rate in diabetic patients [31]. In severe cases, SARS-CoV-2 causes liver injury and higher blood glucose levels [32].

Obesity is also related to more severe SARS-CoV-2 illness [33].

4.4. COVID-19 and venous thromboembolism (VTE)

Patients hospitalized due to COVID-19 are at high risk of VTE [34]. Heparins, especially enoxaparin, were used in one study to reduce the risk for VTE in COVID-19 patients, and they resulted in reducing the mortality in those patients by reducing sepsis-induced coagulopathy [35]. It was hypothesized that in some COVID-19 patients not treated with heparins, the mortality rate was high because they developed pulmonary embolism [34].
4.5. COVID-19 and anxiety/depression

One study indicated that 47.4% of COVID-19 patients suffered from anxiety, and 30.3% of patients suffered from depression [36]. Female patients are more likely to suffer from anxiety/depression than male patients. The study also showed that non-patients with contact history to epidemic areas are more likely to suffer from anxiety/depression. The authors recommend psychological evaluation of confirmed or suspected patients and taking all the necessary interventions, including pharmacological treatment, into account [33].

4.6. COVID-19 and kidney disease

AKI is common in COVID-19 patients in the ICU, with an incidence of 15%. Since renal tubules’ cells have a high expression of ACE2, SARS-CoV-2 can cause direct damage to these cells in addition to the damage caused by the cytokine storm induced by the virus. On the other hand, chronic kidney disease (CKD) is associated with more severe COVID-19 infections. The mortality rate because of pneumonia in CKD patients is 14 – 16 times higher than that in the general population [37].

4.7. Impact of COVID-19 on the digestive system and liver

As discussed earlier, SARS-CoV-2 infection can adversely affect the digestive system causing symptoms such as nausea, vomiting, diarrhea, and abdominal pain. In addition, about 14.8 – 53.1% of COVID-19 patients experience high levels of liver enzymes in the blood. Viral RNA was detected in the feces of COVID-19 patients even after the clearance of the virus from the upper respiratory tract [38].

4.8. Management of COVID-19

In this section, we highlighted the results from computational studies, pre-clinical trials, and clinical trials in the management of COVID-19.

4.9. Results from computational chemistry studies

Several studies were published with the aim of identifying potential targets in SARS-CoV-2 and medications that may work against the virus using computer-based techniques. We summarize in this article some of these studies to highlight some potential anti-SARS-CoV-2 agents that might be worth further investigation. In one study, scientists used computer-based technology to identify host genes that may be related to SARS-CoV-2 activity as well as agents that affect these genes. The most important genes include HSPA4, ILK, and MDM2. The authors suggested that the possible effective drugs may include nimesulide (a cyclooxygenase 2 inhibitor), fluticasone propionate (corticosteroid), thiabendazole (antifungal and anti-inflammatory), and didanosine (targets both adenosine kinase and IL-2 receptor antagonist [IL2RA]). The authors highlighted the role of didanosine with the hypothesis that blocking IL2RA by didanosine may reduce fatality in COVID-19. The hypothesis is on the basis that the hypersecretion of IL-1RA in Ebola virus infection was associated with high fatality. The same results were reported that IL-2RA is hypersecreted in SARS-CoV-2, and hence, it may be associated with fatality rate [39].

Using docking software, Abdo Elfiky tested the affinity of 24 compounds to SARS-CoV-2 RNA-dependent RNA polymerase [40]. This is a very important enzyme in the lifecycle of most RNases. Five FDA-approved compounds showed tight binding to the enzyme. These compounds are galidesivir, remdesivir, tenofovir, sofosbuvir, and ribavirin with binding energy values of −7.0, −7.6, −6.9, −7.5, and −7.8 Kcal/mol, respectively. Setrobuvir, IDX-184 and YAK had binding energy values to the enzyme of −11.55, −11.08, −9.36, and −7.68, respectively [41]. Regarding 3CLpro protease, nicotinamide adenine dinucleotide + hydrogen (NADH) had the highest binding affinity to the enzyme between all nucleotides.

Other researchers built a computational model of SARS-CoV-2 S protein and examined the binding affinity of several compounds to it as well as 3CLpro main protease. As for S protein, coenzyme A, adeflavin, tiludronate, and iomeprol had the highest binding affinities with binding energy values of −11.55, −11.08, −9.36, and −7.68, respectively [41]. Regarding 3CLpro protease, nicotinamide adenine dinucleotide + hydrogen (NADH) had the highest binding affinity with an
energy value of −11.016, followed by adeflavin (−10.339), cangrelor (−10.269), carfilzomib (−8.924), and zanamivir (−8.843). The SARS-CoV-2 3CLpro main protease was studied in another computational study and some potential inhibitors were identified using SCAR protocol [42]. Among the potential inhibitors is itacitinib which had the highest docking score (−9.0), followed by oberadilol (−8.9), telcagepant (−8.8), vidupiprant (−8.7), and pilaralisib (−8.5) [41].

4.10. Results from pre-clinical trials and clinical trials

4.10.1. Antivirals: CQ/HCQ

CQ and HCQ are used mainly in the prevention and treatment of malaria in addition to the management of chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus [43]. However, these agents may play a role in the treatment of COVID-19. The proposed mechanism of action includes two parts. The antiviral part includes interfering with the entry of SARS-CoV-2 into host cells by inhibiting glycosylation of host ACE2 receptors and proteolytic processing in addition to elevating endosomal and lysosomal pH. The immunomodulatory mechanism is through the reduction of cytokine production and decrease of autophagy in the host cells [44,45]. An in vitro study showed that the EC50 of CQ against SARS-CoV-2 was 5.47 µM while that of HCQ was 0.72 µM suggesting that HCQ was 7.6 times more potent than CQ [46]. Conversely, the EC50 values of CQ and HCQ against SARS-CoV-1 were determined to be 6.5 µM and 34 µM, respectively, indicating that CQ was 5 times as potent as HCQ [47].

Two in vitro studies examined the efficacy of CQ and HCQ against SARS-CoV-2 at a multiplicity of infection values. At infection values of 0.01, 0.02, 0.2, and 0.8, CQ had EC50 values of 2.71, 3.81, 7.14, and 7.36 µM, respectively, while HCQ had EC50 values of 4.51, 4.06, 17.31, and 12.96 µM, respectively [48,49].

According to a French study, compared to 12.5% in the control group, 70% of the HCQ treated patients were virologically cured at day 6 post-inclusion \((p = 0.001)\). Furthermore, at day 6 post-inclusion, a comparison among the effect of HCQ as a single treatment, HCQ, and azithromycin in combination and control showed that the percentage of patients who were virologically cured was 57.1%, 100%, and 12.5% in treatment groups, respectively, \((p < 0.001)\) which indicated azithromycin plus HCQ could exert a synergistic effect. In addition, this study pointed out that HCQ was significantly more efficient among patients with symptoms of upper respiratory tract infection and lower respiratory tract infections compared to asymptomatic ones \((p < 0.05)\) [50]. A Chinese study showed that CQ phosphate could inhibit the exacerbation of pneumonia, promote a virus-negative transformation, improve lung imaging, and shorten the course of the disease. During the treatment of more than 100 patients involved, no severe adverse effect was found [51]. A case in Colombia illustrated that the use of CQ (orally 300 mg, base, q12h) and clarithromycin (intravenous 500 mg q12h) could successfully relieve the symptoms, and the patient was discharged after 5 days of treatment [52]. In an open-label, randomized controlled trial (ChiCTR2000029868), 75 patients were given standard of care, including intravenous fluids, supplemental oxygen, regular laboratory testing, SARS-CoV testing, hemodynamic monitoring, and intensive care as control, while the other 75 patients were given standard of care plus HCQ. The result was that among the patients, who received standard of care, 56 patients became virologically negative and 19 patients remained positive, while 53 patients became negative and 22 remained positive among the patients who received standard of care plus HCQ. By day 28, the percentage of negative conversion was 85.4% and 81.3% in the standard of care plus HCQ group and control group, respectively, which indicated that the application of HQC did not significantly contribute to the negative conversion compare to the standard of care only. In addition, the adverse reactions occurrence rate was higher in HCQ group (30%) compared to the control group (10%) [53]. A study showed that the creatine phosphokinase (CK) levels (an indicator of CQ adverse effect) were higher in the group that received a high dose of CQ (7 out of 14 [50%]) compared to the one administered a low dose (6 out of 19 [13.6%]) in patients with severe conditions. These results suggested that high doses of CQ are not recommended in the treatment of severely ill patients for its potential adverse effects.
effects [54]. It is of great significance to monitor the serum electrolytes, blood glucose, hepatic, renal functions, body temperature, respiratory symptoms, and lung imaging [55]. Moreover, a baseline electrocardiogram should be established because both CQ and HCQ have the potential to prolong the corrected QT interval [56]. Other relevant clinical trials are shown in Table 2.

4.10.2. Antivirals: Remdesivir

Remdesivir was originally developed to fight against RNA viruses such as Coronaviridae and Flaviviridae. One in vitro study showed that remdesivir has antiviral activity against SARS-CoV-2 with EC50 of 0.77 µM and EC90 of 1.76 µM in addition to CC50 >100 µM [48]. The low EC50 that remdesivir possesses, in addition to a good safety profile and high selectivity against viral RNA-dependent RNA polymerase, makes it a potential treatment for COVID-19. Shehan et al. added to these properties that SARS-CoV-1 did not develop resistance to remdesivir in addition to the long half-life of remdesivir that allows for once-daily dosing [57]. The EC50 of remdesivir against SARS-CoV-1 and MERS-CoV was investigated and was found to be around 0.07 µM [48,58]. Remdesivir was tested in vitro against the Ebola virus where it showed good inhibition of viral replication in addition to decreasing the severity of symptoms from the disease [59]. Similar results were reported in MERS-CoV [60]. The earlier the remdesivir is used, the better the treatment outcome [57,60].

In a randomized, double-blind, placebo-controlled, multicenter trial (NCT04257656), remdesivir was given to 158 patients intravenously (200 mg on day 1, 100 mg on days 2 – 10) while other 78 patients received placebo (the same volume infusions for 10 days in total) as the control group. The patients in the treatment group (median 18.0 days) improved clinically faster than those in the control group (23.0 days). The rates of improvement in the remdesivir group on days 14 and 28 were numerically higher compared to the control group. Furthermore, the 28-day mortality of the remdesivir group was lower than that of the control group. The decrease in the viral load over time was not significantly different in the two groups. However, all three outcomes, including the time to clinical improvement, mortality, or time to clear the virus, were not statistically different compared to placebo among severely ill COVID-19 patients [61]. In another open-label study, remdesivir was given to 35 patients intravenously (200 mg on day 1 and 100 mg on days 2 – 10). Among these 35 patients, 18 patients started the remdesivir treatment in the ICU and 17 in the infectious disease ward (IDW). Only 21 (63%) patients finished the drug schedule while nine patients in ICU and four patients in IDW stopped because of adverse events (8, 22.8%), death (4, 11.4%), and early discharge (1, 2.9%) after a median of 5 doses. By day 10, four (22.2%) of the ICU patients showed improvement, ten (55.5%) still needed invasive ventilation, and four (22.2%) had died. Among the IDW patients, six patients (35.3%) showed improvement in the hospitalization status, ten (58.8%) still needed high-flow therapy or non-invasive ventilation; one had died (5.8%). As only one of the IDW patients worsened in the hospitalization condition during the follow-up 28 days, remdesivir is possibly more efficacious among early, non-critical patients. The most frequent severe adverse events were hypertransaminasemia (42.8%) and AKI (22.8%) [62]. The safety and efficacy of remdesivir need to be further studied as one of the most likely antiviral drugs to cure COVID-19. Related clinical trials are shown in Table 2.

4.10.3. Antivirals: Umifenovir

Umifenovir is an antiviral agent against influenza approved in Russia and China. An in vitro study showed that umifenovir has activity against SARS-CoV-1 by targeting the S protein/ACE2 interaction and hence decreased the fusion of the viral cell to the cell membrane. An in vitro study showed that umifenovir effectively inhibited SARS-CoV-2 at a concentration of 10-30 µM/L [63].

A study involving 50 patients including Lopinavir/Ritonavir (LPV/r) group (34 patients receiving 400 mg/100 mg of LPV/r, bid) and arbidol group (16 patients receiving 0.2 g of arbidol, 3 times/day, 7 days) indicated that after 14 days of treatment, all cases in arbidol group turned virologically negative while 15 cases (44.1%) in LPV/r group remained positive in RNA test. Furthermore, this report showed that the course of the disease was
### Table 2. Ongoing clinical trials with antiviral drugs for COVID-19 as of October 26, 2020 [71,83]

| NCT/registration number | Title                                                                 | Intervention/comparator                                                                 | Recruitment status | Phase |
|-------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------|-------|
| NCT04362332             | Chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) | Chloroquine or HQC+supportive care/supportive care                                     | Terminated         | IV    |
| NCT04331600             | Chloroquine as antiviral treatment in coronavirus infection 2020 (QUARANTINE2020) | Standard of care+chloroquine phosphate+telemedical approach/standard of care+telemedical approach. | Recruiting         | IV    |
| NCT04351191             | Prophylaxis of exposed COVID-19 individuals with mild symptoms using chloroquine compounds (PRECISE) | Chloroquine or HQC+standard care/standard care+placebo                                  | Recruiting         | IV    |
| NCT04346667             | Post-exposure prophylaxis for asymptomatic SARS-CoV-2 COVID-19 patients with chloroquine compounds (PEACE) | Chloroquine or HQC+standard care/standard care+placebo                                  | Recruiting         | IV    |
| NCT04363866             | A pilot study to assess hydroxychloroquine in patients with SARS-CoV-2 (COVID-19) | HQC/placebo                                                                            | Not yet recruiting | IV    |
| NCT04316377             | Norwegian coronavirus disease 2019 study (no COVID-19)               | HQC+standard care/standard care                                                         | Active, not recruiting | IV    |
| NCT04330495             | Randomized, controlled, double-blind clinical trial comparing the efficacy and safety of chemoprophylaxis with hydroxychloroquine in patients under biological treatment and/or jak inhibitors in the prevention of SARS-CoV-2 infection | HQC/placebo                                                                            | Not yet recruiting | IV    |
| NCT04334967             | Hydroxychloroquine in patients with newly diagnosed COVID-19 compared to standard of care | HQC/vitamin c                                                                          | Suspended          | IV    |
| NCT04384380             | Efficacy and tolerability of hydroxychloroquine in adult patients with COVID-19 | HQC sulphate/standard care                                                              | Recruiting         | IV    |
| NCT04382625             | Hydroxychloroquine in SARS-CoV-2 (COVID-19) pneumonia trial           | HQC/standard care                                                                       | Not yet recruiting | IV    |
| NCT04429867             | Hydroxychloroquine Use in hospitalized patients with COVID-19: impact on progression to severe or critical disease | HQC/placebo                                                                            | Active, not recruiting | IV    |
| NCT04466540             | Randomized placebo-controlled trial of hydroxychloroquine in outpatient cases with coronavirus disease 2019 (COVID-19) (COALITION-V) | HQC/placebo                                                                            | Recruiting         | IV    |
| ChiCTR2000029992         | An open randomized controlled trial for chloroquine phosphate and hydroxychloroquine sulphate in the treatment of severe novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate or HQC sulfate/routine treatment                                 | Not yet recruiting | IV    |

*(Contd...)*
| NCT/registration number | Title                                                                 | Intervention/comparator                                      | Recruitment status | Phase |
|-------------------------|----------------------------------------------------------------------|---------------------------------------------------------------|--------------------|-------|
| ChiCTR2000029899        | Evaluation the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in mild and common patients with novel coronavirus pneumonia (COVID-19) a randomized, open-label, parallel, controlled trial | Chloroquine phosphate or HQC sulfate/blank                    | Recruiting         | IV    |
| ChiCTR2000029868        | Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19) a randomized controlled, open label, multicenter trial | HQC sulfate/conventional treatment                           | Completed          | IV    |
| ChiCTR2000032487        | Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities | HQC sulfate/placebo                                            | Not yet recruiting | IV    |
| ChiCTR2000030718        | Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate/blank                                   | Recruiting         | IV    |
| ChiCTR2000029559        | Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)                                      | HQC/placebo                                                   | Recruiting         | IV    |
| NCT04255017             | A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia | Lopinavir-ritonavir/supportive treatment                      | Recruiting         | IV    |
| NCT02735707             | Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (remap-cap) | Lopinavir-ritonavir/blank                                     | Recruiting         | IV    |
| NCT04255017             | A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia | Lopinavir -ritonavir+symptomatic supportive treatment/symptomatic supportive treatment | Recruiting         | IV    |
| NCT04286503             | The clinical study of carrimycin on treatment patients with COVID-19                                                         | Lopinavir/ritonavir/basic treatment                           | Not yet recruiting | IV    |
| ChiCTR2000029741        | Efficacy of chloroquine and lopinavir/ritonavir in mild/general novel coronavirus (COVID-19) infections a prospective, open-label, multicenter randomized controlled clinical study | Chloroquine phosphate/lopinavir-ritonavir                     | Recruiting         | IV    |
| NCT04350684             | Umifenovir in hospitalized COVID-19 patients (UAIIC)                                                                        | Umifenovir+interferon-β 1a+lpv/r+HQC+standard care/Interferon-β 1a+lpv/r+HQC+standard care | Enrolling by invitation | IV    |

(Contd...)
| NCT/registration number | Title                                                                 | Intervention/comparator                                            | Recruitment status                  | Phase |
|-------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------|-------|
| NCT04260594             | Clinical study of arbidolhydrochloride tablets in the treatment of pneumonia caused by novel coronavirus | Arbidol+basic treatment/basic treatment                             | Not yet recruiting                  | IV    |
| ChiCTR2000029621        | Clinical study of arbidolhydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19) | Arbidol+basic treatment/basic treatment                             | Recruiting                          | IV    |
| NCT04330690             | Treatments for COVID-19 Canadian arm of the solidarity trial (CATCO) | Remdesivir+supportive care/supportive care                          | Recruiting                          | II    |
| NCT04431453             | Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734™) in participants from birth to < 18 years of age with Coronavirus Disease 2019 (COVID-19) (CARAVAN) | Remdesivir/blank                                                    | Not yet recruiting                  | III   |
| NCT04321616             | The efficacy of different anti-viral drugs in COVID-19 infected patients | Remdesivir+standard care/standard care                              | Recruiting                          | III   |
| NCT04315948             | Trial of treatments for COVID-19 in hospitalized adults (discovery) | Remdesivir+standard care/standard care                              | Recruiting                          | III   |
| NCT04252664             | A trial of remdesivir in adults with mild and moderate COVID-19       | Remdesivir/placebo                                                  | Suspended                           | III   |
| NCT04280705             | Adaptive COVID-19 treatment trial (ACTT)                              | Remdesivir/placebo                                                  | Completed                           | III   |
| NCT04409262             | A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia (REMDACTA) | Remdesivir+tocilizumab/remdesivir+placebo                           | Recruiting                          | III   |
| NCT04501952             | Study to evaluate the efficacy and safety of remdesivir (GS-5734™) treatment of coronavirus disease 2019 (COVID-19) in an outpatient setting | Remdesivir/placebo                                                  | Not yet recruiting                  | III   |
| NCT04345419             | Remdesivir versus chloroquine in COVID-19                             | Remdesivir/chloroquine or HQC                                      | Recruiting                          | III   |
| NCT04501978             | Therapeutics for inpatients with COVID-19 (TICO)                     | Remdesivir/placebo                                                  | Recruiting                          | III   |
| NCT04292899             | Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19) | Remdesivir/standard care                                            | completed                           | III   |
| NCT04350671             | Interferon beta 1a in hospitalized COVID-19 patients (IB1alC)         | Interferon-β 1a+lopinavir-ritonavir+single dose of HQC/lopinavir-ritonavir+single dose of HQC | Enrolling by invitation             | IV    |

(Contd...)
significantly longer in the LPV/r group compared to the arbidol group ($p < 0.01$), which suggested that arbidol monotherapy has better clinical efficacy than LPV/r [64]. In addition, in a retrospective cohort study, the combination of arbidol and LPV/r was proved to be more efficient than monotherapy with...
The main adverse reactions of arbidol include slow heart rate, nausea, diarrhea, and it must be avoided in combination with metoprolol, propranolol (Propranol), and other beta receptor antagonists, and when the heart rate is <60 beats/min, it is recommended to stop the application [66].

4.10.4. Antivirals: LPV/r and darunavir-cobicistat
The combination of LPV/r has been approved by the FDA for the treatment of HIV. Against SARS-CoV-1, lopinavir at 4 µg/ml caused inhibition of its growth after 48 h of incubation [67]. In vitro studies showed that lopinavir has an EC50 of 17.1 µM against SARS-CoV-1 [68]. Worth mentioning that the addition of LPV/r to IFNβ against MERS-CoV did not significantly increase the efficacy of IFNβ in vitro or in vivo, but they exacerbated the lung disease in vivo [60]. Another study showed opposite results [69]. Based on a recent study, lopinavir, but not ritonavir, had an EC50 of 26.63 µM against SARS-CoV-2 [70].

In a study in China involving 40 patients, all patients were given LPV/r (200 mg/50 mg/tablet, 2 tablets bid) and traditional Chinese medicine. After 6 – 30 days of admission, new coronavirus nucleic acid turned negative in all patients. In this report, the authors also pointed out that the incidence of adverse reactions of LPV/r was high for total adverse reactions (72.5%), including elevated triglyceride (50%), adverse reactions of the digestive system (42.5%), and termination of the therapy due to intolerable reactions (7.5%), which were mostly related to the digestive system, such as nausea and diarrhea [71]. A critically ill case in Japan was administered LPV/r through a nasogastric tube, the patient was moved out of ICU on day 15 and was discharged on day 24 [72]. However, several other reports argued that LPV/r showed no benefit in clinical improvement [73] or viral clearance [74] compared with standard of care (i.e., necessary supplemental oxygen, non-invasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation [ECMO]). A Chinese study found that among 119 patients who received LPV/r-based antiretroviral treatments regimen, no COVID-19 case occurred. Although the study results failed to indicate that the LPV/r antiretroviral treatment regimen is significantly related to predict reducing COVID-19, it still suggests that LPV/r may act as prophylaxis [75].

The mechanism of action of darunavir and cobicistat is basically the same as LPV/r. Both are protease inhibitors, and cobicistat is also a cytochrome P450 and GP inhibitor [76]. As demonstrated in an in vitro study, darunavir had antiviral activity against SARS-CoV-2 at a concentration of 300 µM [63]. Clinical studies have shown that the gastrointestinal tolerance of darunavir is relatively higher than that of LPV/r, so patients with serious gastrointestinal adverse effects can be treated with darunavir/cobicistat (oral, 1 tablet/day) or favipiravir (first dose 1600 mg, subsequent 600 mg, 3 times/day) [55,66].

Since all above drugs are metabolized by liver cytochrome P450, extra attention should be paid to drug-drug interactions. Patients with hepatic dysfunction should be closely monitored for liver function and adverse reactions during treatment [77].

4.10.5. Antivirals: Ribavirin
Ribavirin is an antiviral that inhibits viral replication by inhibiting RNA-dependent RNA polymerase. It showed activity against SARS-CoV-1 in some studies but, it required high doses such as 1.2 – 2.4 g orally every 8 h [78]. As a treatment against SARS-CoV-2, ribavirin had an EC50 of 109.5 µM which indicated it is 100 times less potent than remdesivir [48].

4.10.6. Antivirals: Favipiravir
Favipiravir is a prodrug which generates an active moiety called favipiravir ribofuranosyl-5’-triphosphate which inhibits the RNA-dependent RNA polymerase enzyme in influenza and Ebola viruses. One in vitro study showed that EC50 of favipiravir against SARS-COV-2 is 61.88 µM [48]. On the other hand, Choy Kt et al. depicted that favipiravir failed to demonstrate any antiviral activity against SARS-CoV-2 in vitro at concentrations below 100 µM/L [70].

4.10.7. Antiviral immunotherapy IFN
Type 1 IFN-1 are a group of cytokines secreted by various cells, especially plasmacytoid dendritic cells. They are recognized by the type 1 IFN heterodimeric receptor complex comprising
IFN-α receptor 1 (IFNAR1) and IFNAR2 subunits on the plasma membrane in most of cells. They can eventually decrease membrane fluidity and prevent membrane fusion by upregulating the expression of the CH25H gene, the protein product of which is an enzyme that can change cholesterol into 25-hydroxycholesterol (25HC). Subsequently, 25HC mediates the infectious cycle at the virus-host membrane fusion step [79]. In SARS-CoV-1, open reading frame (ORF) 3b protein prohibits the phosphorylation of IRF3, which plays a key role in the activation of IFN expression. Furthermore, the ORF6 protein of SARS-CoV inhibits the import of transcriptional factors in the nucleus by disrupting karyopherin transport, which eventually leads to IFN response. The ORF3b and ORF6 proteins are truncated in SARS-CoV-2 that might explain its higher sensitivity to IFN-α as compared to MERS-CoV and SARS-CoV-1 [80]. Both IFNα and IFNβ stimulate innate antiviral responses. They showed activity against MERS-CoV with EC50 of 175 IU/mL [81]. In a clinical research, 77 adults with confirmed COVID-19 were divided into three treatment groups: Nebulized IFN-α2b group (n = 7), arbidol group (n = 24), and IFN-α2b plus arbidol group (n = 46). The average days for viral clearance were 21.1, 27.9, and 20.3 for IFN-α2b group, arbidol group, and IFN-α2b plus arbidol group, respectively, indicated that regardless of the use of arbidol, IFN-α2b can shorten the process of viral clearance. The result suggests that IFN-α2b need to be further explored as a treatment in COVID-19 patients [82]. Related clinical trials are shown in Table 2.

4.10.8. Other antiviral agents

Penciclovir was tested against SARS-CoV-2 in vitro and had an EC50 of 95.96 µM and CC50 >400 µM. Nafamostat was tested in the same study and had EC50 of 22.5 µM and CC50 >100 µM [48]. Oseltamivir was used with other antimicrobials in patients who contracted SARS-CoV-2 in China before its etiology was identified. It is not recommended to use oseltamivir in COVID-19 as SARS-CoV-2 lacks the neuraminidase enzyme (the target of oseltamivir) [84]. Oseltamivir failed to inhibit SARS-CoV-1 even at a concentration of 10,000 µM [81]. However, a case in Thailand showed that the combination of oseltamivir and LPV/r was efficient in improving the conditions and the patient was virologically negative after 48 h of treatment. Furthermore, two patients in Australia recovered successfully from COVID-19 after being treated with oseltamivir [85].

4.11. Immunomodulatory agents

SARS-CoV-2 infection activates CD14+CD16+ monocytes with high expression of IL-6 that contribute to COVID-19 progression. These data suggest that IL-6 inhibitors, such as tocilizumab, may help control COVID-19-induced hyperinflammatory condition, a factor for high mortality in COVID-19 patients [86]. A report examined the elevation of IL-6 among severe COVID-19 patients. The result showed the mean level of serum IL-6 among severe patients was 56.8 pg/mL (41.4 – 72.3 pg/mL), which was significantly higher than 17.3 pg/mL (13.5 – 21.1 pg/mL, p < 0.001) recorded from non-severe patients [87]. Tocilizumab is an IL-6 receptor-specific monoclonal antibody approved by the FDA for the treatment of cytokine release syndrome [88]. However, a research involving three severe cases who received tocilizumab (8 mg/kg, intravenous infusion for more than 1 h) resulted in no significant effect on the level of COVID-19-related inflammatory factors in them [89]. Furthermore, some researchers argued that the utilization of tocilizumab in early stage may promote the replication of the virus as a result of the decrease in IL-6 [90]. Henceforth, the efficacy and safety of tocilizumab in the management of COVID-19 need to be further evaluated.

4.11.1. Anti-S protein monoclonal antibodies

The antibody CR3022 (originally developed to fight SARS-CoV-1) can bind potently to the receptor-binding domain (RBD) within the S protein of SARS-CoV-2 and thus, inhibit its entry to host cells [91]. However, Zheng et al. showed that 85% RBD antibody epitopes in SARS-CoV-2 are significantly altered when compared with SARS-CoV-1, which means that new antibodies are needed for SARS-CoV-2 [92].

4.11.2. Corticosteroids

The use of corticosteroids in the management of SARS-CoV-2 is a double-edged sword. While they reduce the inflammatory response in the lungs and
thereby reduce the risk for acute lung injury and ARDS, they, on the other hand, delay the viral clearance and increase the risk for secondary infection [93]. A study pointed out that severe COVID-19 patients may benefit from precise low-dose corticosteroid treatment [94]. The routine use of corticosteroid is not recommended by the National Health Commission of China. The recommended dose and duration of therapy of methylprednisolone for patients with progressive deterioration of oxygenation indicator, rapid imaging progress, or excessive activation of the inflammatory response in the body is no more than 1 – 2 mg/kg/day for 3 – 5 days. During the management, the condition and efficacy should be evaluated every 2 or 3 days. Compared with hydrocortisone and dexamethasone, methylprednisolone has long elimination half-life (1.8 – 5.2 h) and moderate effect, and it is easy to administer. Furthermore, it exerts a less inhibitory effect on the hypothalamic-pituitary-adrenal axis (HPA). It is directly metabolized by the liver CYP3A4 enzyme to an inactive metabolite; therefore, methylprednisolone is a more suitable therapeutic candidate for COVID-19 [66].

4.11.3. Peptides and proteins-based agents

Heptad repeat 1 and 2 (HR1 and HR2) are from the surface structures that facilitate SARS-CoV-2 entry into host cells. An in vitro study showed that HR2-derived peptides (HR2P) and EK1 (modified HR2P peptide) inhibited the fusion of SARS-CoV-2 to host cells [95]. Nguyen et al. reported a cleaving system for SARS-CoV-2 RNA genome. This CRISPR/Cas13 system contained a Cas13d protein in addition to RNA containing sequences designed specifically to target SARS-CoV-2 RNA genome. The system can be delivered to lung cells by adeno-associated virus (AAV) [96].

One recent study demonstrated that human recombinant soluble ACE2 (hrsACE2) protein inhibits the attachment of SARS-CoV-2 to Vero-E6 cells in a dose-dependent manner [97]. The study also showed that hrsACE2 reduces the infection of human capillary organoids and human kidney organoids by SARS-CoV-2. Lei et al. designed two fusion proteins consisting of the extracellular domain of the human ACE2 attached to Fc domain of human IgG1. Those proteins were able to bind to the RBD on SARS-CoV-2 with high affinity. The in vitro IC50 of the designed proteins against SARS-CoV-2 was 0.03 and 0.1 µg/ml [98].

4.11.4. Vitamin C

Vitamin C, also known as ascorbic acid, has a strong reducing property and can, therefore, be used as antioxidants. It can help to improve the immune system and prevent the oxidation vital biomolecules including proteins, lipids, and DNA. During infection, the level of vitamin decreases and the body’s demand for Vitamin C will increase accordingly [99]. In the management of severe and late stages of COVID-19, the application of Vitamin C could efficiently decrease cytokine storm [100]. Furthermore, it was proved that high-dose Vitamin C infusion can reduce the mortality of patients with ARDS [101]. In a study, intravenous Vitamin C was used as adjuvant therapy for virus-induced ARDS. A 20-year-old woman was infected by enterovirus/rhinovirus and developed dyspnea and hypoxemia, which rapidly developed into acute lung injury, eventually leading to ARDS. ECMO was used for the patient with a large dose of intravenous vitamin C (200 mg/kg every 24 h). After treatment, the patient’s lung gas exchange was significantly improved. After 12 days, the patient was discharged from the hospital without long-term ARDS sequelae [102].

As ARDS considered being the main complication of COVID-19, Vitamin C can be regarded as a potent adjuvant drug. In a retrospective analysis of COVID-19 in 71 cases, all patients were given Vitamin C injection (4 g/time/day, intravenous drip), and the outcome suggested that the application of high-dose Vitamin C may play a key role in the protection of lung tissue [103]. Relevant clinical trials are shown in Table 3.

4.11.5. Antibiotic treatment and other pharmacological therapies

It is reported that the overuse of antibiotic drugs with the absence of infection can induce the secretion of pro-inflammatory cytokines (IL-1b, IL-6, and TNF-α) and eventually lead to sepsis and especially septic shock during the treatment of COVID-19 [104]. Therefore, regular or inappropriate use of antibiotic drugs is not recommended during the treatment, especially in combination with broad-spectrum antibiotic drugs.
In cases where there is a basic disease or evidence that there is a secondary bacterial infection or a severe patient, the symptomatic use of related antibacterial drugs may be considered [55].

Nitazoxanide in in vitro studies against SARS-CoV-2 had an EC50 of 2.12 µM and CC50 > 35.53 µM at 48 h. The active metabolite of nitazoxanide, tizoxanide, was shown to be more potent with an EC50 of 0.92 µM in the same study [48]. Nitazoxanide demonstrated potent activity against MERS-CoV [47]. The mechanism of action of nitazoxanide is believed to be pathways involved in viral replication in addition to those mechanisms that the virus targets host to avoid host defense. This could be the mechanism of activity of nitazoxanide against a range of viruses including influenza, respiratory syncytial virus, rotavirus, norovirus, and coronaviruses [47].

Ivermectin is an FDA-approved agent against parasitic infections. Moreover, it was proved that it can inhibit HIV-1 replication and limit inflammation caused by some RNA viruses such as influenza, dengue, and west Nile viruses. In an in vitro study against SARS-CoV-2, ivermectin reduced the viral RNA by about 5,000 fold after 48 h of its addition to Vero-hSLAM cells infected with SARS-CoV-2 [105].

One study suggested that metronidazole may help to control the inflammatory conditions associated with SARS-CoV-2 by reducing the

| Table 3. Ongoing clinical trials with anti-inflammatory drugs for COVID-19 as of October 26, 2020 [71,83] |
|-------------------------------------------------|-----------------------------------------------|-------------------------------|------------------|
| NCT/registration number | Title | Intervention/comparator | Recruitment status | Phase |
| NCT04363216 | Pharmacologic ascorbic acid as an activator of lymphocyte signaling for COVID-19 treatment | Vitamin c/routine care | Not yet recruiting | II |
| NCT04344184 | Early infusion of Vitamin C for the treatment of novel COVID-19 acute lung injury (EVICT-CORONA-ALI) | Vitamin C/placebo | Not yet recruiting | II |
| NCT04264533 | Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia | Vitamin C/placebo | Recruiting | II |
| NCT04401150 | Lessening organ dysfunction with Vitamin C - COVID-19 (LOVIT-COVID) | Vitamin C/placebo | Recruiting | III |
| NCT04354428 | Treatment for COVID-19 in high-risk adult outpatients | Vitamin c/placebo | Recruiting | III |
| NCT04468139 | The study of quadruple therapy zinc, quercetin, bromelain and Vitamin C on the clinical outcomes of patients infected with COVID-19 | Vitamin c/placebo | Recruiting | IV |
| NCT04263402 | The efficacy of different hormone doses in 2019-nCoV severe pneumonia | Methylprednisolone/blank | Recruiting | IV |
| NCT02735707 | Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP) | Tocilizumab/blank | Recruiting | IV |
| NCT04377750 | The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation | Tocilizumab/placebo | Recruiting | IV |
| ChiCTR2000030894 | Favipiravir combined with tocilizumab in the treatment of novel coronavirus pneumonia (COVID-19) - a multicenter, randomized, controlled trial | Favipiravir+ tocilizumab/favipiravir or tocilizumab | Recruiting | IV |
| ChiCTR2000030580 | Efficacy and safety of tocilizumab combined with adamumab (QLETILI) in severe and critical patients with novel coronavirus pneumonia (COVID-19) | Tocilizumab+ adamumab+ standard care/standard care | Recruiting | IV |
levels of IL-8, IL-6, IL-1β, TNFα, IL-12, and IFNγ in addition to reducing the number of circulating lymphocytes and neutrophil-generated reactive oxygen species [106]. The host cellular serine protease TMPRSS2 interacts with the S protein to facilitate viral entry into host cells. Camostat mesylate in one study inhibited TMPRSS2 and reduced the entry of SARS-CoV-2 into host lung cells [107]. Bromhexine is a transmembrane protease serine inhibitor that has been used as a mucolytic cough suppressant [108]. In China, it is under investigation as a mucolytic drug in suspected and mild patients who have chest congestion and cough (NCT04273763) [109].

4.11.6. Plasma exchange

Plasma exchange is a type of plasmapheresis. It concerns with removing patients’ plasma and exchanging it with fresh plasma, albumin solution, and balanced fluids at the same speed. In this way, the reduction of pathological damage and decrease of pathogenic substances can be achieved. This is also known as extracorporeal blood purification which is widely used in patients with immune diseases [110]. In the first case, the patient showed persisted leukopenia and elevated inflammatory markers, including CRP (105.5 mg/L, reference 0 – 3 mg/L), and IL-6 (54.57 pg/mL, reference 0–7 pg/mL). After receiving three sessions of plasma exchange, the parameters persistently increased. Antiphospholipid antibodies including anti-β2 glycoprotein-I (258.1CU, reference 0 – 20CU) and anticardiolipin (43.2CU, reference 0 – 20CU) were positive on day 26. The presence of these antibodies could indicate an early anticoagulation of patients with COVID-19 [111]. Therefore, a plasma exchange was given on day 29, with two following sessions of plasma exchange. A rapid reduction of the titers of antiphospholipid antibodies and inflammatory marker were observed [112]. In another case with persistent diarrhea, four sessions of plasma exchange followed by intravenous Ig (IVIG) were performed, and the patient’s condition stabilized with no more diarrhea episodes [113]. In addition, a study involving three patients pointed out that after plasma exchange, the level of inflammatory factors significantly decreased for CRP (from 84.81 mg/mL to 9.2 mg/mL) and IL-6 (from 12.14 pg/mL to 4.33pg/mL), which confirmed the effectiveness of plasma exchange therapy in COVID-19 patients [89].

4.11.7. Convalescent plasma or hyperimmune Ig therapy

Convalescent plasma or hyperimmune Ig therapy is defined as the plasma collected from individuals after recovering from the infection and antibody development. With the infusion of convalescent plasma, passive antibodies are transfused into the patients and provide susceptible populations with immediate immunity [114]. Convalescent plasma therapy has been used in the management of many virus infections including SARS, MERS, and Ebola virus [115]. A clinical study carried out by Nanjing University analyzed the efficacy of convalescent plasma among six patients in which all patients were given the transfusion of ABO-compatible convalescent plasma. The result showed that the GGOs of five patients resolved and the density of consolidation reduced after receiving transfusion of convalescent plasma. Among two patients who presented with positive SAR-CoV-2 in throat swab, convalescent plasma therapy could eliminate the virus. In addition, the titers of anti-SARS-CoV-2 antibody in two patients increased immediately. The result suggested that convalescent plasma therapy is clinically beneficial [116]. In addition, two severe cases with ARDS from South Korea showed positive results after receiving convalescent plasma therapy [117]. However, a study showed that all patients turned to virologically negative state by the 3rd day after using convalescent plasma therapy but five of them died eventually. Thus, the researchers argued that the application of convalescent plasma could only improve the results of virological tests but exert no positive effect on reducing the mortality in critically end-stage COVID-19 patients. Furthermore, the researchers pointed out that the treatment should be utilized earlier [118].

4.11.8. Adjuvant therapy

Maintaining a good nutritional status is important for immune system function [119], so it is recommended by Chinese experts to retain the nasogastric tube for gastric nutrition in severe patients. If gastric nutrition is not suitable, a pyloric feeding route, such as nasointestinal tube, should be adopted [55]. In addition, it is recommended by
the National Health Commission of China to use micro-ecological regulators to maintain intestinal micro-ecological balance and prevent secondary bacterial infections [66].

4.11.9. Vaccine

At present, there is still no new drug for COVID-19, and the vaccine is not only cost-effective but also can effectively control disease infection from the source, so the development of vaccines for treatment and prevention is of great significance. At present, S protein is the most promising antigen for the SARS-CoV-2 vaccine not only because it is on the surface of the virus for easier recognition but also it mediates the interaction between the virus and host cell receptor ACE2. Moreover, previous researches on SARS-CoV and MERS-CoV indicated that S protein was a favorable antigen for the development of vaccines [120]. Vaccines that targeted other antigens are also under studies, including whole-cell killed and live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccines, and live vector vaccines [120,121].

In a dose-escalation, single-center, open-label, non-randomized, Phase 1 trial, and an adenovirus type-5 (Ad5) vectored COVID-19 vaccine were investigated. This vaccine used the S glycoprotein of a SARS-CoV-2 strain. In this trial, 108 healthy adults were divided into three dose groups who received intramuscular injections of low-dose \(5 \times 10^{10}\), middle-dose \(1 \times 10^{11}\), and high-dose \(1.5 \times 10^{11}\) viral particles. Within the first 7 days after the injection, the percentage of participants who reported at least one adverse reaction was 83%, 83%, and 75% in the low-, middle-, and high-dose groups, respectively. Among all dose groups, the most common systemic adverse events were fever (46%), fatigue (44%), headache (39%), and muscle pain (17%), of which most were mild or moderate. On day 14, ELISA antibodies and neutralizing antibodies showed a significant increase and specific T-cell responses were noted. On day 28, ELISA antibodies and neutralizing antibodies reached the peak. The result indicated that the Ad5 vectored COVID-19 vaccine need to be further investigated for the control of COVID-19 [122].

In another randomized, double-blind, placebo-controlled, Phase II trial (NCT04341389), the safety and immunogenicity of Ad5 vectored COVID-19 vaccine were investigated. Healthy adults \((n = 603)\) were divided randomly into two vaccine group (high-dose: \(1 \times 10^{11}\) viral particles, \(n = 253\); low-dose: \(5 \times 10^{10}\) viral particles, \(n = 129\) or placebo group \((n = 126)\). On day 28 after a single intramuscular injection in the arm, both doses of vaccine could significantly induce neutralizing antibody. The geometric mean titers of the antibody were 19.5 (95% CI 16.8 – 22.7) and 18.3 (14.4 – 23.3) among the high-dose and low-dose group, respectively. However, 24 participants in high-dose groups and one in low-dose group reported severe adverse effects, none of them were serious reactions. These results indicated the Ad5 vectored COVID-19 vaccine at a dose of \(5 \times 10^{10}\) viral particles is safe and immunogenic [3]. In a single-blind, randomized controlled, Phase I/II trial (NCT04324606), the safety and immunogenicity of a chimpanzee adenovirus vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein was studied. Healthy adults were divided randomly into vaccine group to receive ChAdOx1 nCoV-19 at a dose of \(5 \times 10^{10}\) viral particles or control group to receive a meningococcal conjugate vaccine (MenACWY). Ten participants were involved in a non-randomized, unblinded ChAdOx1 nCoV-19 prime-boost study and received a booster vaccine 28 days after the first administration. The responses of anti-spike IgG increased by day 28 (157 ELISA units, 96-317) and boosted after a second dose (639 ELISA units, 360 – 792, \(n = 10\)). Neutralizing antibody was detected after a single dose of vaccine administration. No serious adverse events were reported [123]. A group of Russian researchers developed a heterologous COVID-19 vaccine consisting of a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector carrying the gene of SARS-CoV-2 spike glycoprotein, rAd26-S and rAd5-S, respectively. Importantly, the vaccine was produced in two formulations, frozen, and lyophilized. Two open, non-randomized Phase I/II studies were carried out to test the safety and immunogenicity of this vaccine. In Phase I study, the safety of the two components was assessed by administering a single intramuscular injection of either rAd26-S or rAd5-S. The result indicated that
both components were safe as no serious adverse reactions were observed. In the Phase II study, participants were assigned to receive rAd26-S on day 0 and rAd5-S on day 21 intramuscularly. On day 42, both formulations of this heterologous vaccine could significantly increase the amount of anti-spike IgG and neutralizing antibody [124]. There are several other ongoing vaccine-related trials that are summarized in Table 4 (data not published yet).

### Table 4. Ongoing clinical trials with vaccines for COVID-19 as of October 26, 2020 [83]

| NCT/registration number | Title                                                                 | Intervention                                                                                     | Recruitment status      | Phase | Country  |
|-------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------|-------|----------|
| NCT04405908             | SCB-2019 as COVID-19 vaccine                                         | SCB-2019/SCB-2019 with AS03 adjuvant/SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant          | Recruiting              | I     | Australia|
| NCT04453852             | Monovalent recombinant COVID-19 vaccine (COVAX19)                    | COVID-19 recombinant spike protein with Advax-SM adjuvant (COVAX-19 vaccine)                    | Recruiting              | I     | Australia|
| NCT04368988             | Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with/without Matrix-M | SARS-CoV-2 rS/SARS-CoV-2 rS with Matrix-M                                                         | Active, not recruiting  | I     | Australia|
| NCT04495933             | A study on the safety, tolerability and immune response of SARS-CoV-2 Sclamp (COVID-19) vaccine in healthy adults | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine                                                        | Recruiting              | I     | Australia|
| NCT04334980             | Evaluating the safety, tolerability and immunogenicity of bacTRL-Spike vaccine for prevention of COVID-19 | bacTRL-Spike                                                                                     | Not yet recruiting       | I     | Australia|
| NCT04369794             | COVID-19 BCG as therapeutic vaccine, transmission limitation, and immunoglobulin enhancement (BATTLE) | Calmette Guerin bacillus vaccine                                                                | Recruiting              | IV    | Brazil   |
| NCT04568811             | The phase I clinical trial of booster vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine | Adenovirus type-5 vectored COVID-19 vaccine                                                      | Active, not recruiting  | I     | China    |
| NCT04551547             | Safety and immunogenicity study of inactivated vaccine for prevention of COVID-19 | Inactivated SARS-CoV-2 vaccine                                                                | Not yet recruiting       | I and II | China |
| NCT04530656             | Phase I trial of a recombinant SARS-CoV-2 vaccine (SF9 Cell)         | Recombinant SARS-CoV-2 vaccine (SF9 Cell)                                                        | Not yet recruiting       | I     | China    |
| NCT04552366             | A clinical trial of a recombinant adenovirus 5 vectored covid-19 vaccine (Ad5-nCoV) With two doses in healthy adults | Ad5-nCoV                                                                                         | Recruiting              | I     | China    |

(Contd...)
| NCT/ registration number | Title                                                                 | Intervention                                                                 | Recruitment status | Phase | Country |
|--------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------|-------|---------|
| NCT04566770             | Phase IIb clinical trial of a COVID-19 vaccine named recombinant novel coronavirus vaccine (adenovirus type 5 vector) | Recombinant novel coronavirus vaccine (adenovirus type 5 vector)              | Recruiting         | II    | China   |
| NCT04550351             | Recombinant new coronavirus vaccine (CHO Cells) to prevent SARS-CoV-2 phase I clinical trial (ria years old) | Recombinant new coronavirus vaccine (CHO cell)                               | Recruiting         | I and II | China   |
| NCT04523571             | Safety and immunogenicity of sars-cov-2 mrna vaccine (BNT162b1) in 36 almette healthy subjects | SARS-CoV-2 mRNA vaccine BNT162b1                                              | Recruiting         | I     | China   |
| NCT04383574             | Safety and immunogenicity study of inactivated vaccine for prevention of SARS-CoV-2 infection (COVID-19) | Inactivated SARS-CoV-2 vaccine                                                 | Active, not recruiting | I and II | China   |
| NCT04470609             | Safety and immunogenicity study of an inactivated SARS-CoV-2 vaccine for preventing against COVID-19 in people aged ≥ 60 years | Inactivated SARS-CoV-2 vaccine                                                 | Enrolling by invitation | I and II | China   |
| NCT04352608             | Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19) | Inactivated SARS-CoV-2 vaccine                                                 | Recruiting         | I and II | China   |
| NCT04412538             | Safety and immunogenicity study of an inactivated SARS-CoV-2 vaccine for preventing against COVID-19 | Inactivated SARS-CoV-2 vaccine                                                 | Recruiting         | I and II | China   |
| NCT04313127             | Phase I clinical trial of a COVID-19 vaccine in 18 – 60 healthy adults (CTCOVID-19) | Ad5-nCoV                                                                     | Active, not recruiting | I     | China   |
| NCT04341389             | A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV) | Ad5-nCoV                                                                     | Active, not recruiting | II    | China   |
| NCT04276896             | Immunity and safety of Covid-19 synthetic minigene vaccine           | LV-SMENP-DC vaccine and antigen-specific CTLs                                | Recruiting         | I and II | China   |
| NCT04299724             | Safety and immunity of COVID-19 aAPC vaccine                         | Pathogen-specific aAPC                                                        | Recruiting         | I     | China   |
| NCT04414267             | Bacillus 27 almette-guérin vaccination to prevent COVID-19 (ACTIVATEII) | Calmette Guerin bacillus vaccine                                              | Recruiting         | IV    | Greece  |

(Contd...)
| NCT/registration number | Title                                                                 | Intervention                                                                                           | Recruitment status          | Phase | Country          |
|-------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|------------------------------|-------|------------------|
| NCT04445428             | OPV as potential protection against COVID-19                         | Oral polio vaccine (OPV)                                                                                | Not yet recruiting          | IV    | Guinea-Bissau     |
| NCT04527575             | Study of the safety, reactogenicity and immunogenicity of “EpiVacCorona” vaccine for the prevention of COVID-19 (EpiVacCorona) | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)          | Active, not recruiting      | I and II | Russia           |
| NCT04587219             | The study of “Gam-COVID-Vac” vaccine against COVID-19 with the participation of volunteers of 60 years old and older | Gam-COVID-Vac                                                                                          | Not yet recruiting          | II    | Russia           |
| NCT04540393             | AZD1222 Vaccine for the Prevention of COVID-19                        | AZD1222                                                                                                 | Not yet recruiting          | III   | Russia           |
| NCT04436471             | An open study of the safety, tolerability and immunogenicity of the drug “Gam-COVID-Vac” vaccine against COVID-19 | Gam-COVID-Vac                                                                                          | Completed                   | I and II | Russia           |
| NCT04437875             | An open study of the safety, tolerability and immunogenicity of “Gam-COVID-Vac Lyo” vaccine against COVID-19 | Gam-COVID-Vac Lyo                                                                                      | Completed                   | I and II | Russia           |
| NCT04527575             | Study of the safety, reactogenicity and immunogenicity of “EpiVacCorona” vaccine for the prevention of COVID-19 (EpiVacCorona) | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)          | Active, not recruiting      | I and II | Russia           |
| NCT04530396             | Clinical trial of efficacy, safety, and immunogenicity of Gam-COVID-Vac vaccine against COVID-19 (RESIST) | Gam-COVID-Vac                                                                                          | Recruiting                  | III   | Russia           |
| NCT04540419             | Clinical trial of recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) against COVID-19 | Recombinant novel coronavirus vaccine (adenovirus type 5 vector)/ placebo                                | Recruiting                  | III   | Russia           |
| NCT04583995             | A study looking at the effectiveness, immune response, and safety of a COVID-19 vaccine in adults in the United Kingdom | SARS-CoV-2 rS/Matrix M1-Adjuvant/placebo                                                              | Recruiting                  | III   | The United Kingdom |
| NCT04400838             | Investigating a vaccine against COVID-19                            | ChAdO × 1 nCoV-19                                                                                      | Recruiting                  | II and III | The United Kingdom |

(Contd...)
| NCT/registration number | Title                                                                 | Intervention                                                                 | Recruitment status       | Phase          | Country        |
|-------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------|----------------|----------------|
| NCT04333732             | CROWN CORONATION: COVID-19 research outcomes worldwide network for Coronavirus prevention (CROWN CORONA) | MR or M-M-R II ® vaccine/placebo                                               | Recruiting               | III            | The United Kingdom |
| NCT04324606             | A study of a candidate COVID-19 vaccine (COV001)                      | ChAdO × 1 nCoV-19/MenACWY vaccine                                               | Active, not recruiting   | I and II       | The United Kingdom |
| NCT04400838             | Investigating a vaccine against COVID-19                             | ChAdO × 1 nCoV-19/MenACWY vaccine                                               | Recruiting               | II and III     | The United Kingdom |
| NCT04591717             | Study of the safety of prophylactic vaccination with 2nd generation E1/E2B/E3-deleted adenoviral-COVID-19 in normal healthy volunteers | hAd5-S-Fusion + N-ETSD vaccine                                                  | Recruiting               | I              | The United States  |
| NCT04563702             | Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults | VXA-CoV2-1                                                                     | Recruiting               | I              | The United States  |
| NCT04537208             | Study of recombinant protein vaccine formulations against COVID-19 in healthy adults 18 years of age and older | SARS-CoV-2 vaccine                                                             | Recruiting               | I and II       | The United States  |
| NCT04368988             | Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS nanoparticle vaccine with/without Matrix-M adjuvant | SARS-CoV-2 rS/Matrix-M adjuvant/placebo                                         | Active, not recruiting   | I and II       | The United States  |
| NCT04336410             | Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers | INO-4800                                                                       | Active, not recruiting   | I              | The United States  |
| NCT04540185             | A phase 3 randomized double-blind efficacy and safety study of oral polio vaccine and NA-831 for Covid-19 (OPV-NA831) | Oral polio vaccine                                                             | Enrolling by invitation | III            | The United States  |
| NCT04498247             | A study to assess safety, tolerability, and immunogenicity of V591 (COVID-19 vaccine) in healthy participants (V591-001) | V591/placebo                                                                  | Recruiting               | I and II       | The United States  |
| NCT04386252             | Phase Ib-II trial of dendritic cell vaccine to prevent COVID-19 in adults | AV-COVID-1                                                                     | Not yet recruiting       | I and II       | The United States  |
5. Conclusion

Despite a considerable amount of research and significant progress, the COVID-19 pandemic has not been effectively controlled worldwide yet and has become the greatest pandemic in the 21st century. Several drugs are currently used in clinical trials, but the safety and efficacy need to be further investigated in larger and diverse populations as well as in different stages. Potential drug and vaccines still need to be studied before being progressed to clinical trials. Notably, vaccine plays a key role in the prevention and the control of transmission of COVID-19. Development of vaccines, rapid point-of-care diagnostic tools and effective targeted treatments are among the high
priorities of research in this area. These are attracting substantial attention and funding. In addition, the virological characteristics of SARS-CoV-2 should be explored more thoroughly so that more potential therapeutic targets can be discovered, leading to safer, and more effective treatment to COVID-19.

Funding

We would like to acknowledge the National Breast Cancer Foundation Research fellowship and grant to Dr. Pegah Varamini (PF-16-007).

Conflicts of interest

Authors have no conflict of interest to declare.

References

[1] Yang, F.; Shi, S.; Zhu, J.; Shi, J.; Dai, K.; Chen, X. Analysis of 92 Deceased Patients with COVID-19. J. Med. Virol., 2020, 11, 2511–5.

[2] Zhu, J.; Ji, P.; Pang, J.; Zhong, Z.; Li, H.; He, C.; Zhang, J.; Zhao, C. Clinical Characteristics of 3,062 COVID-19 Patients: A Meta-analysis. J. Med. Virol., 2020, 92, 1902–14.

[3] Zhu, F.C.; Guan, X.H.; Li, Y.H.; Huang, J.Y.; Jiang, T.; Hou, L.H.; Li, J.X.; Yang, B.F.; Wang, L.; Wang, W.J.; Wu, S.P.; Wang, Z.; Wu, X.H.; Xu, J.J.; Zhang, Z.; Jia, S.Y.; Zheng, J.P.; Hu, Y.; Liu, J.J.; Zhang, J.; Qian, X.A.; Li, Q.; Pan, H.X.; Jiang, H.D.; Deng, P.; Guo, J.B.; Wang, X.W.; Wang, X.H.; Chen, W. Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial. Lancet, 2020, 396(10249), 479–88.

[4] Chen, Y.; Lui, Q.; Guo, D. Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis. J. Med. Virol., 2020, 92(4), 418–23.

[5] Fan, C.; Li, K.; Ding, Y.; Lu, W.; Wang. J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. medRxiv, 2020.

[6] Wen, S.; Xiang, Y.; Fang, W.; Zeng, Y.; Li, B.; Hu, Y.; Lang, C.; Huang, D.; Sun, Q.; Xiong, Y.; Huang, X.; Lv, J.; Luo, Y.; Shen, L.; Yang, H.; Huang, G.; Yang, R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol., 2020, 92(7), 797–806.

[7] Wong, C.K.; Lam, C.W.; Wu, A.K.; Ip, W.K.; Lee, N.L.; Chan, I.H.; Lit, L.C.; Hui, D.S.; Chan, M.H.; Chung, S.S.; Sung, J.J. Plasma Inflammatory Cytokines and Chemokines in Severe Acute Respiratory Syndrome. Clin. Exp. Immunol., 2004, 136(1), 95–103.

[8] Zhang, H.; Kang, Z.; Gong, H.; Hu, D.; Wang, J.; Li, Z.; Cui, X.; Xiao, J.; Meng, T.; Zhou, W.; Liu, J.; Hu, H. The Digestive System is a Potential Route of 2019-nCoV Infection: A Bioinformatics Analysis Based on Single-Cell Transcripts. bioRxiv, 2020.

[9] Guan, W.J.; Liang, W.H.; Zhao, Y.; Liang, H.R.; Chen, Z.S.; Li, Y.M.; Liu, X.Q.; Chen, R.C.; Tang, C.L.; Wang, T.; Ou, C.Q.; Li, L.; Chen, P.Y.; Sang, L.; Wang, W.; Li, J.F.; Li, C.C.; Ou, L.M.; Cheng, B.; Xiong, S.; Ni, Z.Y.; Xiang, J.; Hu, Y.; Liu, L.; Shan, H.; Lei, C.L.; Peng, Y.X.; Wei, L.; Liu, Y.; Hu, Y.H.; Peng, P.; Wang, J.M.; Liu, J.Y.; Chen, Z.; Li, G.; Zheng, Z.; Qiu, S.Q.; Luo, J.; Ye, C.J.; Zhu, S.Y.; Cheng, L.L.; Ye, F.; Li, S.Y.; Zheng, J.P.; Zhang, N.F.; Zhong, N.S.; He, J.X.; China Medical Treatment Expert Group for COVI-19. Comorbidity and its Impact on 1590 Patients with Covid-19 in China: A Nationwide Analysis. Eur. Respir. J., 2020, 55(5), 2000547.
Mederski, B.D.; Shadowitz, S.B.; Gold, W.L.; Hawryluck, L.A.; Rea, E.; Chenkin, J.S.; Ceson, D.W.; Poutanen, S.M.; Detsky, A.S. Clinical Features and Short-term Outcomes of 144 Patients with SARS in the Greater Toronto Area. JAMA, 2003, 289(21), 2801–9.

Aqlahtani, F.Y.; Aleenazy, F.S.; Ali El Hadi Mohamed, R.; Alnazi, M.S.; Mohamed, N.; Alrasheed, M.M.; Abanmy, N.; Alhawase, T. Prevalence of Comorbidities in Cases of Middle East Respiratory Syndrome Coronavirus: A Retrospective Study. Epidemiol. Infect., 2018, 47, 1–5.

Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; Zhao, L.; Fan, H.; Luo, S.; Hu, D. Diabetes is a Risk Factor for the Progression and Prognosis of COVID-19. Diabetes Metab. Res. Rev., 2020, e3319.

Chow, N.; Fleming-Dutra, K.; Gierke, R.; Hall, A.; Hughes, M.; Plishghivi, T.; Cletsky, M.; Royski, K.; Skoff, T.; Ussery, E. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 United States, February 12–March 28, 2020. MMWR Morb. Mortal. Wkly. Rep., 2020, 69(13), 382–6.

Seshasai, S.R.K.; Kaptose, T.; Thompson, A.; Di Angelantonio, E.; Gao, P.; Sarwar, N.; Whincup, P.H.; McMakul, K.J.; Gillum, R.F.; Holme, I.; Njolstad, I.; Fletcher, A.; Nilsson, P.; Lewinton, S.; Collins, R.; Gudnason, V.; Thompson, S.G.; Sattar, N.; Selvin, E.; Hu, F.B.; Danesh, J. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-specific Death. New Engl. J. Med., 2011, 364(9), 829–41.

Jin, X.; Lian, J.S.; Hu, J.H.; Gao, J.; Zheng, L.; Zhang, Y.M.; Hao, S.R.; Jia, H.Y.; Cai, H.; Zhang, X.L.; Yu, G.D.; Ku, J.X.; Wang, X.Y.; Gu, J.Q.; Zhang, S.Y.; Ye, C.Y.; Jin, C.L.; Li, Y.F.; Yu, X.; Yu, X.P.; Huang, J.R.; Xu, K.L.; Ni, Q.; Yu, C.B.; Zhu, B.; Li, Y.T.; Liu, J.; Zhao, H.; Zhang, X.; Yu, L.; Guo, Y.Z.; Su, J.W.; Tao, J.J.; Lang, G.J.; Wu, X.X.; Wu, W.R.; Qiu, T.; Xiong, D.R.; Yi, P.; Shi, D.; Chen, Y.; Ren, Y.; Qiu, Y.Q.; Li, L.J.; Sheng, J.; Yang, Y. Epidemiological, Clinical and Virological Characteristics of 74 Cases of Coronavirus-infected Disease 2019 (COVID-19) with Gastrointestinal Symptoms. Gut, 2020, 69(6), 1002–9.

Lighter, J.; Phillips, M.; Hochman, S.; Sterling, S.; Johnson, D.; Francois, F.; Holme, I.; Njolstad, I.; Fletcher, A.; Nilsson, P.; Lewinton, S.; Collins, R.; Gudnason, V.; Thompson, S.G.; Sattar, N.; Selvin, E.; Hu, F.B.; Danesh, J. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-specific Death. New Engl. J. Med., 2011, 364(9), 829–41.

Henry, B.M.; Lippi, G. Chronic Kidney Disease is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy. J. Thromb. Haemost., 2020, 18(6), 1516–7.

Teng, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant Treatment is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy. J. Thromb. Haemost., 2020, 18(5), 1094–9.

Li, X.; Dai, T.; Wang, H.; Shi, J.; Yuan, W.; Li, J.; Chen, L.; Zhang, T.; Zhang, S.; Kong, Y.; Yue, N.; Shi, H.; He, Y.; Hu, H.; Liu, F.; Yang, C.; Liu, Y. A Randomized Controlled Novel Coronavirus Pneumonia Patients with Anxiety and Depression. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020, 49(1), 203–8.

Henry, B.M.; Lippi, G. Chronic Kidney Disease is Associated with Severe Coronavirus Disease 2019 (COVID-19) Infection. Int. Urol. Nephrol., 2020, 52(6), 1193–4.

Wong, S.H.; Lui, R.N.; Sung, J.J. Covid-19 and the Digestive System. J. Gastroenterol. Hepatol., 2020, 52(6), 1193–4.

Cava, C.; Bertoli, G.; Castiglioni, I. In Silico Discovery of Candidate Drugs against Covid-19. Viruses, 2020, 12(4), 404.

Elfgang, A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesvir, and Tenofovir against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study. Life Sci., 2020, 253, 117592.

Hall, D.C.; Jr., J.H. A Search for Medications to Treat COVID-19 via In Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease. Travel Med. Infect. Dis., 2020, 35, 101646.

Li, S.; Zheng, Q.; Wang, Z. Potential Covalent Drugs Targeting the Main Protease of the SARS-CoV-2 Coronavirus. Bioinformatics, 2020, 36(11), 3295–8.

Savarnino, A.; Boelaert, J.R.; Cassone, A.; Majori, G.; Cauda, R. Effects of Chloroquine on Viral Infections: An Old Drug Against Today’s Diseases. Lancet Infect. Dis., 2003, 3(11), 722–7.

Chow, N.; Fleming-Dutra, K.; Gierke, R.; Hall, A.; Hughes, M.; Plishghivi, T.; Cletsky, M.; Royski, K.; Skoff, T.; Ussery, E. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 United States, February 12–March 28, 2020. MMWR Morb. Mortal. Wkly. Rep., 2020, 69(13), 382–6.

Seshasai, S.R.K.; Kaptose, T.; Thompson, A.; Di Angelantonio, E.; Gao, P.; Sarwar, N.; Whincup, P.H.; McMakul, K.J.; Gillum, R.F.; Holme, I.; Njolstad, I.; Fletcher, A.; Nilsson, P.; Lewinton, S.; Collins, R.; Gudnason, V.; Thompson, S.G.; Sattar, N.; Selvin, E.; Hu, F.B.; Danesh, J. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-specific Death. New Engl. J. Med., 2011, 364(9), 829–41.
Trancheva, I.; Bannister, R.; Park, Y.; Babusis, D.; Clarke, M.O.; Mackman, R.L.; Spahn, J.E.; Palmiotti, C.A.; Siegel, D.; Ray, A.S.; Cihlar, T.; Jordan, R.; Denison, M.R.; Baric, R.S. Broad-spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses. Sci. Transl. Med., 2017, 9(396), eaal3653.

Gordon, C.J.; Tchesnokov, E.P.; Feng, J.Y.; Porter, D.P.; Gottesman, M. The Antiviral Compound Remdesivir Potently Inhibits RNA-dependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus. J. Biol. Chem., 2020, 295(15), 4773–9.

Warren, T.K.; Jordan, R.; Lo, M.K.; Ray, A.S.; Mackman, R.L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H.C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K.S.; Van Tongeren, S.A.; Garza, N.L.; Donnelly, G.; Shurtleff, A.C.; Retzerer, C.J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B.P.; Grimes, E.; Welch, L.S.; Gomba, L.; Wilhelmson, C.L.; Nichols, D.K.; Nuss, J.E.; Nagle, E.R.; Kugelman, J.R.; Palacios, G.; Deoerller, E.; Neville, S.; Carra, E.; Clarke, M.O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K.M.; Trancheva, I.; Feng, J.Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M.R.; Flint, M.; McMullan, L.K.; Chen, S.S.; Feamns, R.; Swaminathan, S.; Mayers, D.L.; Spiroiopoulou, C.F.; Lee, W.A.; Nichol, S.T.; Cihlar, T.; Bavari, S. Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola virus in Rhesus Monkeys. Nature, 2016, 531(7594), 381–5.

Sheahan, T.P.; Sims, A.C.; Leist, S.R.; Schäfer, A.; Won, J.; Gordon, C.J.; Tchesnokov, E.P.; Feng, J.Y.; Porter, D.P.; Gotte, J.; Liu, X.; Chen, H.; Wu, X.; Li, K.; Zhou, X.; Dong, X.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Cao, B.; Wang, C. Remdesivir in Adults With Severe COVID-19: A Randomised, Double-blind, Placebo-controlled, Multicentre Trial. Lancet, 2020, 395, 1569–78.

Antinori, S.; Cossu, M.V.; Roidolo, A.L.; Rech, R.; Bonazzi, C.; Pagani, G.; Gubertini, G.; Coen, M.; Magni, C.; Castelli, A.; Borghi, B.; Colombo, R.; Giorgi, R.; Angelì, E.; Mileto, D.; Milazio, L.; Vimercati, S.; Pellicicotta, M.; Corbellino, M.; Torre, A.; Rusconi, S.; Oreni, L.; Gismundo, M.R.; Giacomelli, A.; Meroni, L.; Rizzardini, G.; Galli, M. Compassionate Remdesivir Treatment of Severe COVID-19 Pneumonia in Intensive Care Unit (ICU) and Non-ICU Patients: Clinical Outcome and Differences in Post-treatment Hospitalisation Status. Pharmacol. Res., 2020, 158, 104899.

Zhao, L.; Lu, S.; Gao, J. Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58–60.

Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G.; Zha, T.; Lu, J.; Xue, Y. Arbidol Monotherapy is Superior to Lopinavir/Ritonavir in Treating COVID-19. J. Infect., 2020, 81(1), c21–3.

Deng, L.; Li, C.; Zeng, Q.; Liu, X.; Li, X.; Zhang, H.; Hong, Z.; Xia, J. Arbidol Combined with LPV/r Versus LPV/r Alone Against Coronavirus Disease 2019: A Retrospective Cohort Study. J. Infect., 2020, 81(1), e1–5.

Xu, K.; Cai, H.; Shen, Y.; Ni, Q.; Chen, Y.; Hu, S.; Li, J.; Wang, H.; Yu, L.; Huang, H.; Qiu, Y.; Wei, G.; Fang, Q.; Zhou, J.; Sheng, J.; Liang, T.; Li, L. Management of Coronavirus Disease 19 (COVID-19): The Zhejiang Experience. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020, 49(1), 147–57.

Chu, C.M.; Cheng, Y.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. Role of Lopinavir/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings. Thorax, 2004, 59(3), 252–6.
Based on Single-cell Transcriptomes. bioRxiv, 2020, https://doi.org/10.1101/2020.03.20.97806.

[84] Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fang, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xie, J.; Wei, Y.; Wu, W.; Xie, Y.; Yin, W.; Li, H.; Miu, L.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet (London, England), 2020, 395(10223), 497–506.

[85] Costanzo, M.; De Giglio, M.A.R.; Roviello, G.N. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenoviro, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr. Med. Chem., 2020, 27(27), 4536–41.

[86] Zhou, Y.; Fu, S.; Zheng, L.; Xiong, D.; Zhao, C.; qi, Y.; Sun, R.; Tian, Z.; Xu, X.; Wei, H. Aberrant Pathogenic GM-CSF ‘T Cells and Inflammatory CD14+CD16+ Monocytes in Severe Pulmonary Syndrome Patients of a New Coronavirus. bioRxiv 2020, 2020, 94576.

[87] Aziz, M.; Fatima, R.; Assaly, R. Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. J. Med. Virol., 2020, 92(11), 2283–5.

[88] Sanders, J.M.; Monogue, M.L.; Jodlowski, T.Z.; Cutrell, J.B. Neutralization of SARS-CoV-2 Spike Pseudotyped Virus by Convalescent Plasma in a Pharmacologically Treated SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical. Mol. Immunol., 2020, 94, 397–406.

[89] Montserrat, N.; Mirazimi, A.; Penninger, J.M. Inhibition of SARS-CoV-2 by Fusion Inhibitors Targeting HR1 Domain in Spike Protein. Cell. Physiol. Biochem, 2020, 56(2), 105974.

[90] Radbel, J.; Narayanan, N.; Bhatt, P.J. Use of Tocilizumab for COVID-19 Infected Cytokine Release Syndrome: A Cautionary Case Report. Chest, 2020, 158(1), e15–9.

[91] Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; Ying, T. Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-specific Human Monoclonal Antibody. Emerg. Microb. Infect., 2020, 9(1), 382–5.

[92] Zheng, M.; Song, L. Novel Antibody Epitope Dominates the Antigenicity of Spike Glycoprotein in SARS-CoV-2 Compared to SARS-CoV. Cell. Mol. Immunol., 2020.

[93] Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical Evidence Does Not Support Corticosteroid Treatment for 2019-nCoV Lung Injury. Lancet (London, England), 2020, 395(10223), 473–5.

[94] Zhou, W.; Liu, Y.; Tian, D.; Wang, C.; Wang, S.; Cheng, J.; Hu, M.; Fang, M.; Gao, Y. Potential Benefits of Precise Corticosteroids Therapy for Severe 2019-nCoV Pneumonia. Signal Transduct. Target. Ther., 2020, 5(1), 18.

[95] Shi, H.; Zhou, C.; He, P.; Huang, S.; Duan, Y.; Wang, X.; Lin, K.; Zhou, C.; Zhang, X.; Zha, Y. Successful Treatment of Plasma Exchange Followed by Intravenous Immunoglobulin in a Critically Ill Patient with 2019 Novel Coronavirus Infection. Int. J. Antimicrob Agents, 2020, 56(2), 105974.

[96] Nguyen, T.M.; Zhang, Y.; Pandolfi, P.P. Virus Against Virus: A Potential Treatment for 2019-nCoV (SARS-CoV-2) and Other RNA Viruses. Cell Res., 2020, 30(3), 189–90.

[97] Montell, K.; Kwon, H.; Prado, P.; Hagekruys, A.; Wimmer, R.A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Del Pozo, C.H.; Prosper, F.; Romero, J.P.; Wirsnsberger, G.; Zhang, H.; Slutsky, A.S.; Conder, R.; Montserrat, N.; Mirazimi, A.; Penninger, J.M. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 2020, 181(4), 905–13.e7.

[98] Lei, C.; Qian, K.; Li, T.; Zhang, S.; Fu, W.; Ding, M.; Hu, S. Neutralization of SARS-CoV-2 Spike Pseudotyped Virus by Recombinant ACE2-Ig. Nat. Commun., 2020, 11(1), 2070.

[99] Carr, A.C.; Rosengrave, P.C.; Bayer, S.; Chambers, S.; Mehrtens, J.; Shaw, G.M. Hypovitaminosis C and Vitamin C Deficiency in Critically Ill Patients Despite Recommended Enteral and Parenteral Intakes. Crit. Care, 2017, 21(1), 300.

[100] Boretti, A.; Banik, B.K. Intrahepatic Vitamin C for Reduction of Cytokines Storm in Acute Respiratory Distress Syndrome. PharmaceutNanomateriali, 2020, 12, 100190.

[101] Hernandez, A.; Papadakos, P.J.; Torres, A.; Gonzalez, D.A.; Vives, M.; Ferrando, C.; Baiza, J. Two Known Therapies Could Be Useful as Adjuvant Therapy in Critical Patients Infected by COVID-19. Rev. Esp. Anestesiol. Reanim., 2020, 67(5), 245–52.

[102] Iii, A.A.F.; Kim, C.; Lepler, L.; Malhotra, R.; Debessa, O.; Natrajan, R.; Fisher, B. J.; Syed, A.; DeWilde, C.; Priday, A.; Kasirajan, V. Intrahepatic Vitamin C as Adjunctive Therapy for Enterovero/Rhinovirus Induced Acute Respiratory Distress Syndrome. World J. Crit. Care Med., 2017, 6(1), 85–90.

[103] Linjie, H.; Fuchao, C.; Xueqiang, J.; Zhihao, L.; Wan, W. Clinical characteristics and therapy of novel corona virus pneumonia: 71 cases retrospective analysis. Central South Pharmacy 2020, (18), 739–42.

[104] Hantoukhazadeh, S.; Norooznezhad, A.H. Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19). Arch. Med. Res., 2020, 51(4), 347–348.

[105] Caly, L.; Duce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro. Antiviral Res., 2020, 178, 104787.

[106] Shao et al.
With SARS-CoV-2 infection. Chest, 2020, 158(1), e9–13.

[118] Zeng, Q.L.; Yu, Z.J.; Gou, J.J.; Li, G.M.; Ma, S.H.; Zhang, G.F.; Xu, J.H.; Lin, W.B.; Cui, G.L.; Zhang, M.M.; Li, C.; Wang, Z.S.; Zeng, Z.H.; Liu, Z.S. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. J. Infect. Dis., 2020, 222(1), 38–43.

[119] Calder, P.C.; Carr, A.C.; Gombart, A.F.; Eggersdorfer, M. Optimal Nutritional Status for a Well-Functioning Immune System is an Important Factor to Protect against Viral Infections. Nutrients, 2020, 12(4), 1181.

[120] Zhang, J.; Zeng, H.; Gu, J.; Li, H.; Zheng, L.; Zou, Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines (Basel), 2020, 8(2), 153.

[121] Ahn, D.G.; Shin, H.J.; Kim, M.H.; Lee, S.; Kim, H.S.; Myoung, J.; Kim, B.T.; Kim, S.J. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol., 2020, 30(3), 313–24.

[122] Feng-Cai, Z.; Li, Y.H.; Guan, X.H.; Hou, L.H.; Wang, W.J.; Li, J.X.; Wu, S.P.; Wang, B.S.; Wang, L.; Lian, J.; Li, S.Y.; Jiang, H.D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.B.; Xu, S.B.; Xu, J.J.; Wang, X.W.; Wang, W.; Chen, W. Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-escalation, Open-label, Non-randomised, First-in-human Trial. Lancet, 2020, 395(10240), 1845–54.

[123] Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belji-Rammerstorfer, S.; Bellamy, D.; Bibli, S.; Bittray, M.; Clutterbuck, E.A.; Dold, C.; Faust, S.N.; Fina, A.; Flaxman, A.L.; Hallis, B.; Heath, P.; Jenkin, D.; Lazarus, R.; Makinson, R.; Minassian, A.M.; Pollock, K.M.; Ramasamy, M.; Robinson, H.; Snape, M.; Tarrant, R.; Voysey, M.; Green, C.; Douglas, A.D.; Hall, A.V.S.; Lambe, T.; Gilbert, S.C.; Pollard, A.J.; Abouge, J.; Adams, K.; Ali, A.; Allen, E.; Allison, J.L.; Anslow, R.; Arne-Barnes, E.H.; Babbage, G.; Baille, K.; Baker, M.; Baker, N.; Baker, P.; Baleanu, I.; Ballamnin, J.; Barnes, E.; Barrett, J.; Bates, L.; Batten, A.; Beadon, K.; Beckley, R.; Berrie, E.; Berry, L.; Beveridge, A.; Biewley, K.R.; Bijker, E.M.; Bingham, T.; Blackwell, L.; Blundell, C.L.; Bolam, E.; Boland, E.; Borthwick, N.; Bower, T.; Boyd, A.; Brenner, T.; Bright, P.D.; Brown-O’Sullivan, C.; Brun, E.; Burbage, J.; Burge, S.; Buttiiegi, K.R.; Byard, N.; Puig, I.C.; Calvert, A.; Camara, S.; Cao, M.; Cappuccini, F.; Carr, M.; Carroll, M.W.; Carter, V.; Cathie, K.; Challis, R.J.; Charlton, S.; Chelysheva, I.; Cho, J.S.A.; Cicconi, P.; Cifuentes, L.; Clark, H.; Clark, E.; Cole, T.; Colin-Jones, R.; Conlon, C.P.; Cook, A.; Coombes, N.S.; Cooper, R.; Cosgrove, C.A.; Coy, K.; Crocker, W.E.M.; Cunningham, C.J.; Damratoski, B.E.; Dando, L.; Datoo, M.S.; Davies, H.; De Graaf, H.; Demissie, T.; Di Maso, C.; Dietrich, I.; Dong, T.; Donnellan, F.R.; Douglas, N.; Downing, C.; Drake, J.; Drake-Brockman, R.; Drury, R.E.; Dunachie, S.J.; Edwards, N.J.; Edwards, F.D.L.; Edwards, C.J.; Elias, S.C.; Elmore, M.J.; Emary, K.R.W.; English, R.; Drury, R.; Erokhova, A.S.; Erokhova, A.S.; Faries, C.; Fatahi-Alaoui, A.; Tait, M.; Talbot, H.; Tanner, R.; Taylor, I.J.; Taylor, V.; Te Water Naude, R.; Thakur, N.; Themistocleous, V.; Themistocleous, A.; Thomas, M.; Thomas, T.M.; Thompson, A.; Thomson-Hill, S.; Tomlins, J.; Tonks, S.; Towner, J.; Tran, N.; Tree, J.A.; Truby, A.; Turkentine, K.; Turner, C.; Turner, N.; Turner, S.; Ulaszewska, M.; Varughese, R.; Van Doremalen, N.; Veighey, K.; Verheul, M.K.; Vichos, I.; Vitale, E.; Walker, L.; Watson, M.E.; Welham, B.; Wheat, J.; White, R.; White, R.; Wright, D.; Wright, S.; Yao, X.L.; Yau, Y. Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial. Lancet, 2020, 396(10249), 467–78.